Literature DB >> 10569750

Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

H V Nielsen1, S L Lauemøller, L Christiansen, S Buus, A Fomsgaard, E Petersen.   

Abstract

Infection with the protozoan parasite Toxoplasma gondii is transmitted to humans from infected animals by tissue cysts and oocysts excreted by cats. Immunization with inactivated parasites or recombinant proteins has at best shown partial protection. We constructed a plasmid expressing the SAG1 surface antigen of T. gondii, p1tPASAG1, and showed that animals immunized with the plasmid produce anti-SAG1 antibodies which recognize the native SAG1. Mice immunized with p1tPASAG1 showed 80 to 100% protection against challenge with the non-cyst-producing, virulent RH isolate, compared to an 80% mortality in mice immunized with empty plasmid, which is the greatest efficacy of any vaccine against T. gondii produced so far. The SAG1 molecule was analyzed for potential cytotoxic T-lymphocyte (CTL) epitopes, and four peptides with the best fit were synthesized. The ability of the peptides to stimulate gamma interferon production by CD8(+) T cells from p1tPASAG1-immunized mice was tested in an ELISPOT assay, and one new CTL epitope was identified. Adoptive transfer of CD8(+) T cells from p1tPASAG1-immunized to naïve mice showed partial protection. In conclusion, DNA vaccination with p1tPASAG1 gave effective protection in mice against T. gondii infection and the protection could be adoptively transferred by purified CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569750      PMCID: PMC97042          DOI: 10.1128/IAI.67.12.6358-6363.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Is an HIV vaccine possible?

Authors:  A J McMichael; T Hanke
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

2.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

3.  The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice.

Authors:  Y Suzuki; J S Remington
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

4.  Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii.

Authors:  R Gazzinelli; Y Xu; S Hieny; A Cheever; A Sher
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

5.  Live and killed vaccines against toxoplasmosis in mice.

Authors:  H Waldeland; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

6.  CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice.

Authors:  S J Parker; C W Roberts; J Alexander
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

7.  Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes.

Authors:  R Bülow; J C Boothroyd
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

8.  Conformationally appropriate expression of the Toxoplasma antigen SAG1 (p30) in CHO cells.

Authors:  K Kim; R Bülow; J Kampmeier; J C Boothroyd
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant.

Authors:  D Buxton; K Thomson; S Maley; S Wright; H J Bos
Journal:  Vet Rec       Date:  1991-08-03       Impact factor: 2.695

10.  Trial of a novel experimental Toxoplasma iscom vaccine in pregnant sheep.

Authors:  D Buxton; A Uggla; K Lövgren; K Thomson; A Lundén; B Morein; D A Blewett
Journal:  Br Vet J       Date:  1989 Sep-Oct
View more
  31 in total

1.  Long-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii.

Authors:  Alberto Fachado; Alexandro Rodriguez; Judith Molina; Jaline C Silvério; Ana P M P Marino; Luzia M O Pinto; Sergio O Angel; Juan F Infante; Yara Traub-Cseko; Regina R Amendoeira; Joseli Lannes-Vieira
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

2.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

3.  Effect of rSAG-1(P30) immunisation on the circulating and tissue parasites in guinea pigs as determined by quantitative PCR.

Authors:  Pierre Flori; Laëtitia Tardy; Alain Jacquet; Bahrie Bellete; Jamal Hafid; Hélène Raberin; Roger Tran Manh Sung
Journal:  Parasitol Res       Date:  2006-01-17       Impact factor: 2.289

4.  Class I major histocompatibility complex presentation of antigens that escape from the parasitophorous vacuole of Toxoplasma gondii.

Authors:  Marc-Jan Gubbels; Boris Striepen; Nilabh Shastri; Mustafa Turkoz; Ellen A Robey
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22

6.  Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.

Authors:  Valentina Martin; Alicia Supanitsky; Pablo C Echeverria; Silvana Litwin; Tamara Tanos; Adolfo R De Roodt; Eduardo A Guarnera; Sergio O Angel
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

7.  Differential regulation of effector- and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells.

Authors:  Douglas C Wilson; Gijsbert M Grotenbreg; Kenian Liu; Yanlin Zhao; Eva-Maria Frickel; Marc-Jan Gubbels; Hidde L Ploegh; George S Yap
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

8.  Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice.

Authors:  Melina Laguía-Becher; Valentina Martín; Mauricio Kraemer; Mariana Corigliano; María L Yacono; Alejandra Goldman; Marina Clemente
Journal:  BMC Biotechnol       Date:  2010-07-15       Impact factor: 2.563

9.  The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.

Authors:  Alaa Bassuny Ismael; Dalila Sekkai; Christine Collin; Daniel Bout; Marie-Noëlle Mévélec
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection.

Authors:  T Scorza; S D'Souza; M Laloup; J Dewit; J De Braekeleer; H Verschueren; M Vercammen; K Huygen; E Jongert
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.